Faeth appoints co-founder Karen Vousden to board as Class II director

Sensei Biotherapeutics, Inc.

Board expanded from 5 to 6 directors; Vousden appointed effective Sept 11, 2026, serving until 2029 annual meeting.
Vousden, 68, is a cancer biologist, co-founded Faeth in April 2019, and leads at Francis Crick Institute since 2017.
Also appointed to Compensation Committee; receives standard director cash retainer and option for 25,000 shares under 2026 Equity Plan.
Option vests monthly over 3 years, with full vesting upon change in control; no family or 404(a) transactions disclosed.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Karen Vousden

Class II Director

SNSE · Sensei Biotherapeutics, Inc.

Effective: 2026-09-11
Filed: September 17, 2026, 4:15 PM ET

On September 11, 2026, the Board of Directors (the “Board”) of Faeth Therapeutics, Inc. (the “Company”) increased the size of the Board from five to six directors and appointed Karen Vousden, Ph.D. to serve as a Class II director, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Karen Vousden was appointed as Class II Director at Sensei Biotherapeutics, Inc..

Action: appointed
Role: Class II Director

Exact text from the filing

On September 11, 2026, the Board of Directors (the “Board”) of Faeth Therapeutics, Inc. (the “Company”) increased the size of the Board from five to six directors and appointed Karen Vousden, Ph.D. to serve as a Class II director, effective immediately.

View on SEC.gov

Sensei Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-394360

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.